High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease.
Eleven patients with Hodgkin's disease relapsed from or refractory to conventional-dose chemotherapeutic regimens including MOPP and ABVD were treated by means of high-dose chemotherapy (either single agent melphalan or high-dose cyclophosphamide. VP 16 and BCNU) with bone-marrow rescue (autologous 9, allogeneic 2). Of the 11 patients treated, there were five complete and three partial remissions, with one toxic death. High-dose chemotherapy has the potential for achieving a substantial remission rate in Hodgkin's disease even after failure of conventional-dose chemotherapy.